Wockhardt Drug Filings Seen Delayed After U.S. FDA Alert

Wockhardt Ltd., an Indian maker of insulin and hepatitis vaccines, will not win new drug approvals this year for about half the pending applications in the U.S. after that nation’s regulator placed import curbs on a plant.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.